KR20240161963A - Covid-19을 예방하는 데 사용하기 위한 재조합 뉴캐슬병 바이러스 및 면역원성 조성물 - Google Patents

Covid-19을 예방하는 데 사용하기 위한 재조합 뉴캐슬병 바이러스 및 면역원성 조성물 Download PDF

Info

Publication number
KR20240161963A
KR20240161963A KR1020247033613A KR20247033613A KR20240161963A KR 20240161963 A KR20240161963 A KR 20240161963A KR 1020247033613 A KR1020247033613 A KR 1020247033613A KR 20247033613 A KR20247033613 A KR 20247033613A KR 20240161963 A KR20240161963 A KR 20240161963A
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
protein
seq
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247033613A
Other languages
English (en)
Korean (ko)
Inventor
피터 팔레스
아돌포 가르시아-사스트레
플로리안 크래머
웨이나 선
아이린 곤잘레스 도밍게즈
Original Assignee
이칸 스쿨 오브 메디슨 엣 마운트 시나이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이칸 스쿨 오브 메디슨 엣 마운트 시나이 filed Critical 이칸 스쿨 오브 메디슨 엣 마운트 시나이
Publication of KR20240161963A publication Critical patent/KR20240161963A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247033613A 2022-03-10 2023-03-09 Covid-19을 예방하는 데 사용하기 위한 재조합 뉴캐슬병 바이러스 및 면역원성 조성물 Pending KR20240161963A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263318640P 2022-03-10 2022-03-10
US63/318,640 2022-03-10
PCT/US2023/064063 WO2023173032A2 (en) 2022-03-10 2023-03-09 Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19

Publications (1)

Publication Number Publication Date
KR20240161963A true KR20240161963A (ko) 2024-11-13

Family

ID=87936013

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247033613A Pending KR20240161963A (ko) 2022-03-10 2023-03-09 Covid-19을 예방하는 데 사용하기 위한 재조합 뉴캐슬병 바이러스 및 면역원성 조성물

Country Status (11)

Country Link
US (1) US20250186578A1 (https=)
EP (1) EP4489779A2 (https=)
JP (1) JP2025509352A (https=)
KR (1) KR20240161963A (https=)
CN (1) CN119317446A (https=)
AU (1) AU2023231285A1 (https=)
CA (1) CA3245533A1 (https=)
CL (1) CL2024002683A1 (https=)
CO (1) CO2024012344A2 (https=)
MX (1) MX2024011049A (https=)
WO (1) WO2023173032A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2251034T3 (pl) * 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
MX2022013934A (es) * 2020-05-07 2023-02-22 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo.
US20250041402A1 (en) * 2021-09-30 2025-02-06 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof

Also Published As

Publication number Publication date
CN119317446A (zh) 2025-01-14
EP4489779A2 (en) 2025-01-15
AU2023231285A1 (en) 2024-07-25
JP2025509352A (ja) 2025-04-11
US20250186578A1 (en) 2025-06-12
CA3245533A1 (en) 2023-09-14
MX2024011049A (es) 2024-09-18
WO2023173032A2 (en) 2023-09-14
CO2024012344A2 (es) 2024-12-30
CL2024002683A1 (es) 2025-01-03
WO2023173032A3 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
CN111088283B (zh) mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
US9701723B2 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
ES2929942T3 (es) Vacunas contra el virus de la gripe y sus usos
US10752916B2 (en) Parainfluenza virus 5 based vaccines
US20230310583A1 (en) Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof
US20250041402A1 (en) Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof
US20250228929A1 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
JP2012527232A (ja) 遺伝子組換え改変ワクシニアアンカラウイルス（ｍｖａ）ベースのインフルエンザ万能ワクチン
US11179459B1 (en) Vaccine composition for preventing human infection of SARS coronavirus and alleviating infection symptoms
US20230414745A1 (en) Influenza virus encoding a truncated ns1 protein and a sars-cov receptor binding domain
US20250186578A1 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19
US20240199705A1 (en) Chimeric newcastle disease virus expressing apmv hn and f proteins
Ljungberg et al. DNA vaccination of ferrets with chimeric influenza A virus hemagglutinin (H3) genes
US20250250304A1 (en) Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof
KR20080093382A (ko) 독감 예방용 백신 조성물
Pérez et al. Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters
Lai Overcoming Maternal Antibody Interference in Swine Influenza: Advancing DNA Vaccine Strateies for Enhanced Immune Protection in Piglets
Yang A novel method to produce an avian influenza vaccine bearing membrane-bound cytokines

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000